Sprint Bioscience AB (publ)

Stockholm Stock Exchange SPRINT.ST

Sprint Bioscience AB (publ) Free Cash Flow Yield on January 14, 2025: 21.03%

Sprint Bioscience AB (publ) Free Cash Flow Yield is 21.03% on January 14, 2025, a -24.13% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Sprint Bioscience AB (publ) 52-week high Free Cash Flow Yield is 37.95% on February 05, 2024, which is 80.41% above the current Free Cash Flow Yield.
Sprint Bioscience AB (publ) 52-week low Free Cash Flow Yield is 14.57% on October 24, 2024, which is -30.71% below the current Free Cash Flow Yield.
Sprint Bioscience AB (publ) average Free Cash Flow Yield for the last 52 weeks is 23.78%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: SPRINT.ST

Sprint Bioscience AB (publ)

CEO	Mr. Johan Emilsson
IPO Date	Nov. 7, 2014
Location	Sweden
Headquarters	Novum
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

Key trends

Past 5 years